These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Low-Dose Corticosteroid Combined With Mycophenolate Mofetil for IgA Nephropathy With Stage 3 or 4 CKD: A Retrospective Cohort Study.
    Author: Zhao J, Ma F, Bai M, Sun S.
    Journal: Clin Ther; 2021 May; 43(5):859-870. PubMed ID: 33863547.
    Abstract:
    PURPOSE: This study assessed the long-term (10-year) tolerability and efficacy of a low-dose corticosteroid combined with mycophenolate mofetil (CS + MMF) in the treatment of immunoglobulin A nephropathy (IgAN) with stage 3/4 chronic kidney disease and proteinuria in clinical practice in China. METHODS: Data from patients with biopsy-proven IgAN, stage 3/4 chronic kidney disease (estimated glomerular filtration rate 15-59 mL/min/1.73 m2), and proteinuria (urinary protein excretion ≥1.0 g/d) and who were treated with uncontrolled supportive care (USC), CS, or CS + MMF between January 2008 and December 2017 were included. The primary end point was the prevalence of the composite outcome of any of the following conditions: a reduction in estimated glomerular filtration rate of ≥50%, end-stage renal disease, and death. FINDINGS: Of the 120 enrolled patients, 44, 25, and 51 were treated with USC, CS, and CS + MMF, respectively. The median follow-up time was 40.1 months (IQR, 29.1-67.8 months). The prevalences of the composite outcome were 63.6%, 56.0%, and 19.6%, respectively (P < 0.001). The cumulative 5-year renal function-preservation rates were 48.1%, 51.4%, and 83.7%. After adjustment for covariates, the prevalence of the composite outcome was significantly decreased with CS + MMF (HR = 0.094; 95% CI, 0.026-0.335; P < 0.001), but not with CS (HR = 0.749; 95% CI, 0.354-1.583; P = 0.449), compared with USC. However, 4 patients in the CS + MMF group died, of whom 3 had severe pneumonia. IMPLICATIONS: CS + MMF may have more promising efficacy than USC or CS in renal-function preservation in patients with IgAN and chronic kidney disease in the Chinese population. However, attention should be paid to the increased risk for death due to severe pneumonia.
    [Abstract] [Full Text] [Related] [New Search]